J. Stern & Co. LLP Acquires 673 Shares of Eli Lilly and Company (NYSE:LLY)

J. Stern & Co. LLP lifted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 23.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 3,485 shares of the company's stock after acquiring an additional 673 shares during the quarter. Eli Lilly and Company accounts for about 0.3% of J. Stern & Co. LLP's holdings, making the stock its 25th biggest holding. J. Stern & Co. LLP's holdings in Eli Lilly and Company were worth $2,690,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Highline Wealth Partners LLC lifted its stake in shares of Eli Lilly and Company by 80.0% in the 4th quarter. Highline Wealth Partners LLC now owns 45 shares of the company's stock valued at $35,000 after acquiring an additional 20 shares during the last quarter. FPC Investment Advisory Inc. boosted its holdings in shares of Eli Lilly and Company by 358.3% during the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock worth $45,000 after purchasing an additional 43 shares during the period. Prudent Man Investment Management Inc. bought a new position in Eli Lilly and Company during the 4th quarter valued at approximately $48,000. Compass Financial Services Inc purchased a new stake in Eli Lilly and Company in the 4th quarter worth approximately $50,000. Finally, Fiduciary Advisors Inc. bought a new stake in shares of Eli Lilly and Company in the 4th quarter worth approximately $58,000. Institutional investors own 82.53% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. StockNews.com upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Friday, February 7th. The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and decreased their price objective for the stock from $892.00 to $888.00 in a report on Tuesday, April 8th. Wells Fargo & Company lifted their target price on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. Leerink Partners set a $950.00 price objective on shares of Eli Lilly and Company in a report on Friday, January 17th. Finally, Guggenheim cut their price objective on Eli Lilly and Company from $973.00 to $928.00 and set a "buy" rating on the stock in a research report on Monday, April 14th. Two research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $1,017.00.

Eli Lilly and Company Stock Up 2.9 %

Shares of LLY stock traded up $25.21 during mid-day trading on Friday, hitting $884.94. The company's stock had a trading volume of 3,395,903 shares, compared to its average volume of 3,439,004. The stock has a market cap of $839.07 billion, a price-to-earnings ratio of 75.57, a PEG ratio of 1.40 and a beta of 0.51. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53. The business has a 50-day moving average price of $827.69 and a 200 day moving average price of $818.61.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the sale, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. This represents a 14.62 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.